AbbVie (ABBV) : Zacks Investment Research ranks AbbVie (ABBV) as 3, which is a Hold recommendation. 6 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 more believe that the stock has more downside risks, hence they propose a Strong Sell. A total of 6 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 13 research analysts is 2.23, which indicates as a Buy.
AbbVie (ABBV) has been rated by 13 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $90 and the lowest price target forecast is $47. The average forecast of all the analysts is $72 and the expected standard deviation is $10.71.
For the current week, the company shares have a recommendation consensus of Buy. AbbVie (NYSE:ABBV): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $66.86 and $66.70 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $67.11. The buying momentum continued till the end and the stock did not give up its gains. It closed at $66.95, notching a gain of 0.78% for the day. The total traded volume was 4,246,610 . The stock had closed at $66.43 on the previous day.
In a related news, The Securities and Exchange Commission has divulged that Schumacher Laura J, Officer (Executive Vice President) of AbbVie Inc., had unloaded 186,106 shares at an average price of $60.07 in a transaction dated on June 24, 2016. The total value of the transaction was worth $11,179,387.
AbbVie Inc. (AbbVie) is a global, research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Companys products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohns disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinsons disease; complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. AbbVie also has a pipeline of new medicines, including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties, such as immunology, virology/liver disease, oncology, renal disease, neurological diseases and womens health. The Companys product portfolio includes HUMIRA, HCV products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products.